Skip to main content
Fig. 1 | BMC Molecular and Cell Biology

Fig. 1

From: Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics

Fig. 1

Effect of TMZ and a TRPA1 agonist and inhibitor on cell viability and intracellular ROS levels. TMZ (200 μΜ) significantly reduced the viability of U251 cells (A). No significant effect of TRPA1 agonist PF-4840154 or TRPA1 inhibitor HC030031 treatment on cell viability (C, G) or intracellular ROS levels (E, I) was observed in U251 cells at any treatment dose. Additionally, no significant effect of treatment with the TRPA1 agonist PF-4840154 or TRPA1 inhibitor HC030031 on cell viability (B, D and H) or intracellular ROS levels (F, J) in SHG-44 cells was observed at any dose. TMZ treatment or PF-4840154 and TMZ cotreatment decreased the viability of the U251 cells (K) and SHG-44 cells (L). *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001

Back to article page

BMC Molecular and Cell Biology

ISSN: 2661-8850

Contact us